There has been increasing interest in the use of 5% imiquimod cream in the treatment of patients with superficial basal cell carcinomas (sBCCs). To date, the reports of its efficacy apply to single tumors in individuals.1-3 However, in clinical practice it is common for patients to have more than 1 sBCC when they present for treatment.4 The aim of this study was to assess the safety and efficacy of 2 dosing regimens of 5% imiquimod cream for the treatment of patients with multiple sBCCs.
Marks R, Owens M, Walters S, for the Australasian Multi-Centre Trial Group. Efficacy and Safety of 5% Imiquimod Cream in Treating Patients With Multiple Superficial Basal Cell Carcinomas. Arch Dermatol. 2004;140(10):1284–1285. doi:10.1001/archderm.140.10.1284-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: